Oasmia

Oasmia is a specialty pharmaceutical company focused on developing new treatment options for hard-to-treat cancer patients. It has a growing portfolio of clinical-stage assets targeting advanced cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a collaboration with Elevar Therapeutics, Inc. The development pipeline includes Cantrixil, in clinical development for advanced ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Oasmia possesses proprietary drug delivery technology aimed at enhancing solubility, efficacy, and safety.